LISDEXAMFETAMINE IN THE MANAGEMENT OF BINGE-EATING DISORDER COMORBID WITH GENERALIZED ANXIETY DISORDER: AN INTEGRATIVE REVIEW OF CLINICAL EVIDENCE

Abstract

Binge-Eating Disorder (BED) is one of the most prevalent eating disorders in adults, associated with obesity, metabolic complications, and significant psychological distress. The coexistence of Generalized Anxiety Disorder (GAD) further increases clinical severity and complicates treatment strategies. Lisdexamfetamine, originally developed for ADHD, is currently the only medication approved for the treatment of BED in adults. Randomized controlled trials and meta-analyses consistently demonstrate its efficacy in reducing binge episodes and preventing relapse, particularly at doses of 50–70 mg/day. However, its effects on anxiety remain uncertain: while some studies report symptom improvement, others describe stability or worsening, underscoring the need for individualized monitoring. This integrative review included 32 studies from PubMed and BVS published within the last five years. Findings confirm lisdexamfetamine as an effective intervention for BED but highlight the need for caution in patients with comorbid GAD. In conclusion, although lisdexamfetamine represents a relevant therapeutic advance in the management of binge-eating, its role in comorbid conditions still requires longitudinal evidence to support safe and personalized clinical practice.